Sidus Stem-Free Shoulder IDE Study

Rheumatoid Arthritis Clinical Trial

Official title:

Multicenter Trial of the Sidus Stem-Free Shoulder Arthroplasty System

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01878253
• Other study ID #: CIU2012-12E
• Secondary ID: G130026
• Status: Completed
• Phase: N/A
• Start date: July 2013
• Est. completion date: January 2019

Study information

• Verified date: July 2019
• Source: Zimmer Biomet
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if Sidus stem-free shoulder system is safe and effective when used in total shoulder replacement.

Description:

The primary objectives of this study are to evaluate the safety and efficacy (defined as follows) of the Sidus Stem-Free Shoulder System in unilateral primary total shoulder arthroplasty.

Safety: Will be evaluated by monitoring the frequency and incidence of device related adverse events or unanticipated adverse device effects (UADEs) in investigational subjects as well as analyzing survivorship using revision or intended revision as an endpoint.

Efficacy: Will be determined by comparing the overall pain and functional performance, survivorship and radiographic success of investigational subjects with those subjects who received the control devices.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 95
• Est. completion date: January 2019
• Est. primary completion date: May 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

• Patient must be 22 years of age or older.

• Patient is skeletally mature.

• Patient must have signed the IRB/EC approved informed consent.

• Patient is a candidate for a total shoulder arthroplasty (replacement of humeral head and glenoid).

• Patient has a diagnosis of primary osteoarthritis of the shoulder of grade III or higher.

• Patient has experienced symptoms of shoulder pain and/or loss of function for at least 6 months and has a maximum ASES score of 40.

• Patient has no findings to indicate an etiology of acute trauma, infection, avascular necrosis or inflammatory arthropathy of the operative shoulder.

• Patient has undergone no previous reconstructive shoulder surgery. Acceptable previous shoulder surgeries include arthroscopy, soft tissue repair, or pinning/screw fixation due to a historic fracture.

• Patient is willing and able to comply with the required post-operative therapy as defined in the protocol.

• Patient is willing and able to comply with the required follow-up schedule as defined in the protocol.

Exclusion Criteria:

• Patient is a prisoner.

• Patient is a known current alcohol or drug abuser.

• Patient has a psychiatric illness or cognitive deficit that precluded informed consent.

• Patient has a chronic renal impairment or failure.

• Patient sensitivity to implant materials.

• Patient has a vascular insufficiency due to large or small vessel disease which could inhibit postoperative healing.

• Patient is currently receiving or has received within the last 3 months chronic systemic or inhaled steroids. This exclusion does not apply to those patients with occasional inhaler use due to seasonal allergies.

• Local rash or skin infection around the intended operative site.

• Patients with ongoing Worker's Compensation or third party liability claims related to the operative shoulder.

• Pre-existing contra-lateral shoulder replacement less than 6 months ago.

• Patient who will require a contra-lateral shoulder replacement less than 6 months from the current planned shoulder replacement.

• Patient has evidence of major joint trauma, infection, avascular necrosis, cuff tear arthropathy, chronic dislocation, massive rotator cuff tear, inflammatory arthropathy, or previous shoulder surgery (other than arthroscopy, soft tissue repair, or pinning/screw fixation due to historic fracture).

• Patient has significant muscle paralysis.

• Patient has Charcot arthropathy.

• Patient has metaphyseal bony defects at the bone/implant interface which could inhibit prosthesis fixation.

• Patient has a preoperative computed tomography scans or other radiographic images of the shoulder that showed insufficient glenoid or humeral bone stock to allow for implantation of the prosthesis.

• Insufficient bone stock exists in the presence of metabolic bone disease (i.e. osteoporosis or severe osteopenia), cancer and radiation.

• Patient with severe glenoid deficiency.

• Prior fracture of the operative shoulder with the presence of malunion or non-union.

• Prior tuberosity fracture with the presence of malunion or non-union.

• Patient has an active joint or systemic infection.

• Patient has a life expectancy of less than two years.

• Patient with unacceptably high operative risk.

• Patient unwilling to sign protocol required informed consent.

• Patient is unwilling to complete the protocol required radiographic imaging.

• Patient is unwilling to complete the protocol required follow-up of two years.

• Patient is known to be pregnant.

• Intraoperative findings which indicate insufficient bone stock or local deformities which could inhibit prosthesis fixation. Final assessment of bone quality will be completed intraoperatively upon resection of the humeral head and prior to insertion of the anchor as described in the surgical technique. If there is any doubt regarding bone quality affecting the stable fixation of the anchor, the surgeon must use a stemmed prosthesis.

Related Conditions & MeSH terms

• Arthritis, Rheumatoid
• Joint Diseases
• Osteoarthritis
• Posttraumatic Arthrosis
• Rheumatoid Arthritis

Intervention

Device:
• Sidus Stem-Free Total Shoulder Arthroplasty System

Locations

Country	Name	City	State
Canada	University of Calgary Sports Medicine Clinic	Calgary	Alberta
Canada	Kingston General Hospital	Kingston	Ontario
Canada	St. Joseph's Health Care London - Hand and Upper Limb Centre	London	Ontario
United States	St. Joseph's Hospital of Atlanta	Atlanta	Georgia
United States	MedStar Health	Baltimore	Maryland
United States	Penn State Milton S. Hershey Medical Center	Hershey	Pennsylvania
United States	Norton Orthopaedic & Sports Medicine	Louisville	Kentucky
United States	Rothman Institute	Philadelphia	Pennsylvania
United States	Stanford University	Redwood City	California
United States	Washington University	Saint Louis	Missouri
United States	University of California San Francisco - Orthopaedics Institute	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Zimmer Biomet

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain and Function as Measured by the American Society of Shoulder and Elbow Surgeons Questionnaire	Pain and function as measured by the American Society of Shoulder and Elbow Surgeons questionnaire. ASES consists of 3 subcomponent scores including pain, instability and activities of daily living. The pain score can be 0 to 10 with 0 being no pain and 10 being the worst pain imaginable. The instability score can be 0 to 10 with 0 being no instability and 10 being the worst instability imaginable. The activities of daily living consists of 10 questions with ordinal responses of 0, 1, 2, and 3. 3 involves no limitation and 0 is unable to do. The 3 subcomponents combine to make the overall ASES score which can range from 0 to 100 with 0 being the worst possible score and 100 being the best.	Two years
Primary	Absence of Radiographic Evidence of Failure or Pending Failure Based on Radiographic Assessment	absence of radiographic evidence of pending failure of the humeral components, assessed at 2 years which may include the following: implant fracture; progressive implant migration or subsidence = 5 mm	Two years
Primary	The Number of Device Related Serious Adverse Events.	This outcome will measure the frequency of device related serious adverse events.	Two years
Primary	Survivorship	The Kaplan-Meier method was used for this study. This outcome measures survivorship of the implanted devices from the date of implantation to the date of revision or intended revision up to 2 years post-operative (whichever came first).	Up to Two years
Secondary	ASES Functional and Pain Scores at Intervals Other Than 2 Years as Measured by the American Society of Shoulder and Elbow Surgeons Questionnaire	Pain and function as measured by the American Society of Shoulder and Elbow Surgeons questionnaire. ASES consists of 3 subcomponent scores including pain, instability and activities of daily living. The pain score can be 0 to 10 with 0 being no pain and 10 being the worst pain imaginable. The instability score can be 0 to 10 with 0 being no instability and 10 being the worst instability imaginable. The activities of daily living consists of 10 questions with ordinal responses of 0, 1, 2, and 3. 3 involves no limitation and 0 is unable to do. The 3 subcomponents combine to make the overall ASES score which can range from 0 to 100 with 0 being the worst possible score and 100 being the best.	6 weeks, 6 months, and 1 year
Secondary	SF-12 Mental Health and Physical Composite Scores as Measured by the SF-12 Scoring Questionnaire.	SF-12 Mental Health and Physical Composite Scores. SF-12 is a validated health survey that uses 12 questions to measure functional health and well being from the patient's point of view. The SF-12 is calculated on a scale of 0 to 100, where a 0 is the worst level of health and 100 is the best level of health. The scores are then normalized with a mean score of 50 and a standard deviation of 10, so that scores greater than 50 represent a health level better than average, and scores less than 50 represent a level lower than average.	Pre-Op, 6 weeks, 6 months, 1 year and 2 years